
Arcturus Therapeutics (ARCT) Stock Forecast & Price Target
Arcturus Therapeutics (ARCT) Analyst Ratings
Bulls say
Arcturus Therapeutics Holdings Inc. has reported promising interim data for its ARCT-810 program, showcasing statistically significant improvements in biomarker measures with a favorable safety profile, which bodes well for its ongoing product development. Management highlighted the potential value of the LUNAR LNP platform and exclusive mRNA purification technology, which could drive advancements in various indications beyond cystic fibrosis. Additionally, the continued engagement from key opinion leaders indicates a sustained interest in the company's pipeline, suggesting the possibility for future breakthroughs despite current limitations in clinical data.
Bears say
Arcturus Therapeutics Holdings Inc. faces a negative outlook primarily due to disappointing interim Phase 2 trial results for its ARCT-032 therapy, which failed to demonstrate a meaningful improvement in lung function measured by FEV1, leading to the exclusion of this asset from valuations. Additionally, the company's decision to delay the U.S. launch and remove the LUNAR-COVID Vaccine Global Profit Share from financial models has resulted in significant downward revisions of price targets by analysts. Key risks that compound this negative outlook encompass potential safety issues, ineffective clinical trial results, delays in timelines, and challenges in sufficiently funding operations.
This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcturus Therapeutics (ARCT) Analyst Forecast & Price Prediction
Start investing in Arcturus Therapeutics (ARCT)
Order type
Buy in
Order amount
Est. shares
0 shares